S
Schrodinger
Biotech & Life Sciences · New York City, United States · Founded 1990 · IPO 2020
Computational drug designing for pharmaceutical and biotechnology research MoreLess
Schrödinger operates a cutting-edge computational platform that supports the research initiatives of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Founded in 1990, the company is dedicated to advancing science and talent to enhance its platform. Schrödinger also engages in both wholly-owned and collaborative drug discovery programs across various therapeutic areas. The business model revolves around providing advanced computational tools and services to its clients, which include a diverse range of organizations in over 70 countries. Revenue is generated through software licensing, collaborative research agreements, and drug discovery partnerships. Keywords: computational platform, biopharmaceutical research, drug discovery, academic institutions, government laboratories, therapeutic areas, software licensing, collaborative research, global reach, science investment.
Company overview
Schrodinger company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1990
- Headquarters
- New York City, United States
- Employees
- 1,003
- Open positions
- 8
- Dealroom signal
- 76.1
- Investment activity
- 4 companies · latest May 2024
- Capital deployed
- $187M
- Preferred round
- ACQUISITION
Valuation & funding
Schrodinger funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2024 | $10M | — | Bill & Melinda Gates Foundation | ↗ |
| GRANTOther financing | Nov 2021 | $4.9M | — | Bill & Melinda Gates Foundation | ↗ |
| POST IPO EQUITYOther financing | Aug 2020 | $347M | — | Undisclosed | ↗ |
| IPOOther financing | Feb 2020 | $232M | — | Undisclosed | ↗ |
| SERIES FOther financing | May 2019 | $110M | $440M | WuXi AppTec · Bill Gates · Invus · Bill & Melinda Gates Foundation | — |
| SERIES EOther financing | Jan 2019 | Bill Gates · Qiming Venture Partners · Baron Capital · Bill & Melinda Gates Foundation | ↗ | ||
| LATE VCOther financing | Nov 2018 | Undisclosed | — | ||
| GROWTH EQUITY VCOther financing | Jun 2015 | Scott Becker | — | ||
| GROWTH EQUITY VCOther financing | Dec 2012 | Bill Gates | — | ||
| LATE VCOther financing | Apr 2010 | Bill Gates · Cascade Investment | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $235M | -8.3% | −$142M | -60.4% |
| 2025 | $256M | +23.3% | −$209M | -81.7% |
| 2024 | $208M | -4.2% | −$209M | -100.6% |
| 2023 | $217M | +19.7% | −$225M | -104% |
| 2022 | $181M | +31.2% | −$124M | -68.7% |
| 2021 | $138M | +27.6% | −$120M | -87% |
| 2020 | $108M | — | −$86M | -79.1% |
Growth signals
Schrodinger website traffic
Latest recorded traffic for Schrodinger is 150K monthly website visits, down 6.3% over the last three months. Schrodinger's team grew 24.3% over the past year.
Hiring
Open positions at Schrodinger
Current openings linked to this company in Dealroom.
Comparisons
Schrodinger compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Schrodinger investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ajax TherapeuticsNew York City, United StatesDeveloping targeted therapies for hematologic cancers through innovative cytokine signaling pathways
$2.3Bvaluation
Xtal BioStructuresUnited States
$6Mvaluation
Morphic TherapeuticWaltham, United StatesBiotechnology company developing a new generation of oral integrin therapies
$2.2Bvaluation
Talent graph
Schrodinger's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Schrodinger has talent and traffic
team presence
In the news
Latest news about Schrodinger
Recent press, funding announcements, and product moves mentioning Schrodinger — open to read from the original sources.
Market sentiment
What the market is saying about Schrodinger
An AI-synthesized read of the highest-engagement posts about Schrodinger on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Schrodinger’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.